A Phase III, Randomized, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Disease Types: Hepatocellular

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06921785?term=Rilvegostomig%20&viewType=Card&cond=Hepatocellular%20Carcinoma&rank=1

An Interventional Phase 1b/2, Open-Label Study to Investigate the Safety, Antitumor Activity, and Pharmacokinetics of PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer

Disease Types: Urothelial

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT07421700?term=PF-08634404%20&viewType=Card&cond=Urothelial%20Carcinoma&rank=1

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Disease Types: Pancreatic

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma

For More Information:

https://clinicaltrials.gov/study/NCT07522073?term=INCB161734&viewType=Card&rank=3

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localized High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06952803?term=Adjuvant%20Saruparib%20(AZD5305)%20in%20Patients%20with%20BRCAm&viewType=Card&rank=1

A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Combination with Docetaxel as Second-Line Treatment in Adults with Metastatic Non-Small Cell Lung Cancer or in Combination with Pembrolizumab as First-Line Treatment

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT07353957?term=MCLA-158-CL04&viewType=Card&rank=1

A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.inum-based, concurrent chemoradiation therapy

Disease Types: Lung

Available at: Blacksburg, Roanoke, Salem, Wytheville, Alleghany

For More Information:

https://clinicaltrials.gov/study/NCT07361497?cond=Lung%20Cancer&term=Pumitamig%20&viewType=Card&rank=3

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

Disease Types: Gastrointestinal

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

For More Information:

https://clinicaltrials.gov/study/NCT06596694?term=A%20Phase%201%2F2%20Study%20to%20Evaluate%20the%20Safety%20and%20Efficacy%20of%20Patritumab%20Deruxtecan%20in%20Gastrointestinal%20Cancers&rank=1

A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Disease Types: Colon

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT07221357?term=NCT07221357&rank=1

A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Disease Types: Gastrointestinal

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT07221149?term=NCT07221149&rank=1

An Interventional Phase 1b/2 Study To Evaluate The Safety And Efficacy Of Pf-08634404 Monotherapy And In Combination With Other Anticancer Agents In Adult Participants With Locally Advanced Or Metastatic Renal Cell Carcinoma

Disease Types: Renal

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT07227415?term=NCT07227415&rank=1

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T cell redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer.

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT07164443?term=NCT07164443&rank=1

A Phase 3, Randomized, Double-blind, PlaceboControlled Study Of Mevrometostat (PF-06821497) With Enzalutamide In Metastatic Castration-sensitive Prostate Cancer (MEVPRO-3)

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3, Randomized, Double-blind, PlaceboControlled Study Of Mevrometostat (PF-06821497) With Enzalutamide In Metastatic Castration-sensitive Prostate Cancer (MEVPRO-3)

For More Information:

https://clinicaltrials.gov/study/NCT07028853?term=MEVROMETOSTAT%20in%20prostate&rank=2

A Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Disease Types: Myelomas

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT07095452?term=NCT07095452&rank=1

A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

Disease Types: Leukemia, Lymphoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT07221500?term=NX-5948-201&rank=1

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Disease Types: Leukemia, Lymphoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06973187?term=BGB-16673%20in%20CLL&rank=3

A randomized, Phase 3, open-label study to evaluate PF-08046054/SGN-PDL1V vs Docetaxel in adult participants with previously-treated programmed cell death ligand (PD-L1) positive non-small cell lung cancer (NSCLC)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT07144280?term=%09NCT07144280&rank=1

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT07190248?term=MK-1084%20KRAS%20G12c%20mutant&rank=4

A Phase II Study Investigating Fruquintinib plus FOLFIRI as Second-Line Treatment for Participants with Metastatic Colorectal Cancer

Disease Types: Colon

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase II Study Investigating Fruquintinib plus FOLFIRI as Second-Line Treatment for Participants with Metastatic Colorectal Cancer

For Additional Information:

https://clinicaltrials.gov/study/NCT07011576?term=NCT07011576&rank=1

An Interventional, Phase 3, Double-blind, Randomized Study To Evaluate The Efficacy And Safety Of Pf-08634404 In Combination With Chemotherapy Versus Bevacizumab In Combination With Chemotherapy In Treatment-naïve Participants With Metastatic Colorectal Cancer

Disease Types: Colon

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For Additional Information:

https://clinicaltrials.gov/study/NCT07222800?term=Pf-08634404&rank=4

A randomized, open label, multicenter, Phase 2 study to evaluate the safety and efficacy of two dose levels of ONO-4578 with OpdivoÂ® in combination with mFOLFOX6 and bevacizumab versus standard of care for first-line treatment of non-MSI-H/dMMR, PD-L1 positive advanced colorectal cancer

Disease Types: Colon

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06948448?term=ONO-4578&rank=6

A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients newly diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) advanced GEP-NET with high disease burden (NETTER-3) Protocol No.: CAAA601A62301

Disease Types: Gastrointestinal, Gastroenteropancreatic neuroendocrine tumors

Available at: Roanoke

For More Information:

https://clinicaltrials.gov/study/NCT06784752?term=%09NCT06784752&rank=1

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06136624?term=Opevesostat&rank=7

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM):SUCCESSOR-2 (CA057008)

Disease Types: Myelomas

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT05552976?term=NCT05552976&rank=1

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)

Disease Types: Lymphoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT05139017?term=Zilovertamab%20Vedotin%20%20participants%20with%20DLBCL&rank=7

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)

Disease Types: Lymphoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs InvestigatorÂ’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)

For More Information:

https://clinicaltrials.gov/study/NCT06911502?term=Golcadomide%20in%20combination%20with%20Rituximab%20in%20Follicular%20Lymphoma&rank=3

A Phase 1/2 Substudy of the MK-9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Disease Types: Cholangiocarcinoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 1/2 Substudy of the MK-9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

For More Information:

https://clinicaltrials.gov/study/NCT06428409?term=%20MK-2870%20Monotherapy%20or%20in%20Combination%20With%20Other%20Anticancer%20Agents%20in%20Gastrointestinal%20Cancers&rank=1

A Phase 1b/2, Open-Label, Multicohort Study of Disitamab Vedotin in Adults with HER2 Expressing Advanced Breast Cancer

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 1b/2, Open-Label, Multicohort Study of Disitamab Vedotin in Adults with HER2 Expressing Advanced Breast Cancer

For More Information:

https://clinicaltrials.gov/study/NCT06966453?term=Disitamab%20Vedotin%20in%20Adults%20with%20HER2%20Expressing%20Advanced%20Breast%20Cancer&rank=1

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (TroFuse-032)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT07007780?term=sacituzumab%20tirumotecan&cond=breast%20cancer&rank=2

A Phase III, Randomized, Double-Blind, Multicenter, Global Study of Rilvegostomig in Combination with Chemotherapy for First-line Treatment of Patients with Metastatic Non-squamous Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06627647?term=%20(ARTEMIDE-Lung03)&rank=1

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT05899608?term=%20Ivonescimab%20Versus%20Pembrolizumab%20&rank=2

An open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS) (CA245-0004)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06773910?term=An%20open-label,%20randomized%20study%20of%20BMS-986489%20small-cell%20lung%20cancer%20&rank=1

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Disease Types: Cholangiocarcinoma

Available at: Roanoke

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

For More Information:

https://clinicaltrials.gov/study/NCT05727176?term=Futibatinib%2020%20mg%20and%2016%20mg%20in%20Patients%20with%20Advanced%20Cholangiocarcinoma%20with%20FGFR2%20Fusions%20or%20Rearrangements&rank=1

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06492616?term=STML-ELA-0422&rank=1

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06312176?term=MK-2870-010&rank=1

Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

For More Information:

https://clinicaltrials.gov/study/NCT06230185?term=%20(B-STRONGER-I)%20(01-PS-001)&rank=1

A phase 3 study of fixed dose combinations of fianlimab and cemiplimab versus relatlimab and nivolumab in participants with unresectable or metastatic melanoma.

Disease Types: Melanoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A phase 3 study of fixed dose combinations of fianlimab and cemiplimab versus relatlimab and nivolumab in participants with unresectable or metastatic melanoma.

For More Information:

https://clinicaltrials.gov/study/NCT06246916?term=R3767-ONC-22122&rank=1#more-information

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Disease Types: Myelomas

Available at: Roanoke

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

For More Information:

https://clinicaltrials.gov/study/NCT05972135?term=Teclistamab%20in%20Multiple%20myeloma&rank=2

A Randomized, Open-label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK2140) in Combination With R-CHP versus R-CHOP in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (waveLINE-010)

Disease Types: Lymphoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06717347?term=waveLINE-010&rank=1

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma

Disease Types: Lymphoma

Available at: Roanoke

For More Information:

https://clinicaltrials.gov/study/NCT06191744?term=Epcoritamab%20%2B%20Rituximab%20and%20Lenalidomide%20(R2)&rank=4

A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06646276?term=BMS-986489%20&rank=3

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More information:

https://clinicaltrials.gov/study/NCT06103864?term=D7630C00001&rank=1

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Patients with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Disease Types: Head and Neck

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06256588?term=dostarlimab%20in%20head%20and%20neck%20carcinomas&checkSpell=&rank=1

A phase III randomized, open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Disease Types: Head and Neck

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06525220?term=MCLA-158-CL03&rank=1

A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Disease Types: Head and Neck

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

clinicaltrials.gov- Petosemtamab trial

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Disease Types: Colon, Solid Tumors

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

For More Information:

clinicaltrials.gov- Petosemtamab trial

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment (JZP598-303)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

Clinicaltrials.gov- Zanidatamab

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) (CAAA617D12302)

Disease Types: Prostate

Available at: Roanoke

For More information:

https://clinicaltrials.gov/study/NCT05939414?term=An%20International,%20Prospective,%20Open-label,%20Multi-center,%20Randomized%20Phase%20III%20Study%20comparing%20lutetium%20(177Lu)%20vipivotide%20tetraxetan%20versus%20Observation%20to%20delay%20castration%20or%20disease%20recurrence%20in%20adult%20male%20patients%20with%20prostate-specific%20membrane%20antigen%20(PSMA)%20positive%20Oligometastatic%20Prostate%20Cancer%20(OMPC)%20(CAAA617D12302)&rank=1

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The “ELEMENT-MDS” Trial

Disease Types: Hematology

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT05949684?term=A%20Phase%203,%20Open-label,%20Randomized%20Study%20to%20Compare%20the%20Efficacy%20and%20Safety%20of%20Luspatercept%20(ACE-536)%20vs%20Epoetin%20Alfa%20for%20the%20Treatment%20of%20Anemia%20Due%20to%20Revised%20International%20Prognostic%20Scoring%20System%20(IPSS-R)%20Very%20Low,%20Low,%20or%20Intermediate-Risk%20Myelodysplastic%20Syndrome%20(MDS)%20in%20Erythropoiesis-Stimulating%20Agent%20(ESA)-naive%20Participants%20who%20are%20Non-Transfusion%20Dependent%20(NTD):%20The%20%E2%80%9CELEMENT-MDS%E2%80%9D%20Trial&rank=1

Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

For More Information:

https://clinicaltrials.gov/search?term=Phase%202%20Single%20Arm%20Trial%20with%20a%20Safety%20Lead-in%20of%20Tucatinib%20in%20Combination%20with%20Doxil%20for%20the%20Treatment%20of%20HER2%2B%20Metastatic%20Breast%20Cancer%20(BRE%20381)

A Phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of GDC-6036 in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT04449874?term=NSCLC%20G12C%20mutation%20GDC-6036%20&rank=1

A Phase 2 Study of Alisertib in Patients with Extensive Small Cell Lung Cancer

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 2 Study of Alisertib in Patients with Extensive Small Cell Lung Cancer

For More information:

https://clinicaltrials.gov/study/NCT06095505?term=A%20Phase%202%20Study%20of%20Alisertib%20in%20Patients%20with%20Extensive%20Small%20Cell%20Lung%20Cancer&rank=1

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT05633654?term=%20A%20Randomized,%20Open-label,%20Phase%203%20Study%20of%20Adjuvant%20Sacituzumab%20Govitecan%20and%20Pembrolizumab%20Versus%20Treatment%20of%20Physicians%20Choice%20in%20Patients%20with%20Triple%20Negative%20Breast%20Cancer%20Who%20Have%20Residual%20Invasive%20Disease%20After%20Surgery%20and%20Neoadjuvant%20Therapy&rank=1

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT06136624?term=A%20Phase%203%20Randomized,%20Open-label%20Study%20of%20MK-5684%20Versus%20Alternative%20Abiraterone%20Acetate%20or%20Enzalutamide%20in%20Participants%20With%20Metastatic%20Castration-resistant%20Prostate%20Cancer%20(mCRPC)%20Previously%20Treated%20With%20Next-generation%20Hormonal%20Agent%20(NHA)%20and%20Taxane-based%20Chemotherapy&rank=1

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

For More Information:

https://clinicaltrials.gov/study/NCT05074810?term=NCT05074810&rank=1

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Disease Types: Colon

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

For More Information:

https://clinicaltrials.gov/study/NCT04793958?term=A%20Randomized%20Phase%203%20Study%20of%20MRTX849%20in%20Combination%20with%20Cetuximab%20Versus%20Chemotherapy%20in%20Patients%20with%20Advanced%20Colorectal%20Cancer%20with%20KRAS%20G12C%20Mutation%20with%20Disease%20Progression%20On%20or%20After%20Standard%20First-Line%20Therapy&rank=1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment

Disease Types: Melanoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment

For more information:

https://clinicaltrials.gov/ct2/show/NCT04609566?cond=A+phase+2+study+of+brentuximab+vedotin+in+combination+with+pembrolizumab+in+subjects+with+metastatic+solid+malignancies+after+progression+on+prior+PD-1+inhibitor+treatment&draw=2&rank=1